Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2019 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, Nov 2, 2018
Slide 1: Press Release: Alkem reports Q2FY19 and H1FY19 Results
.1> ALKEM in ALKEM LABORATORIES LTD. o and beynd... To achieve value driven leadership Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Industry Health Care Through Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Indian Quality that is infinite Email : [email protected] Websi
Slide 2: Operational Highlights: India Business
<8> ALKEM VISI MOO ON in ALKEM LABORATORIES LTD. value driven leadership Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, To achieve Care Industry and beyond... Health Through Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Indian is infinite Email : [email protected] Website
Slide 3: US Sales, R&D Investments and FDA Inspection Update
<8> ALKEM mom V1151014 ALKEM LABORATORIES LTD. To achieve value driven leadership in Care Industry and beyond... Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Health Through Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Indian that is infinite Email : [email protected] W
Slide 4: Q2FY19 and H1FY19 Conference Call
<0> ALKEM ALKEM LABORATORIES LTD. iv achieve value driven leadership in Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Indian Health Care Industry and beyond... Throughinfinite Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 QUality that is cares Email : [email protected] W
Slide 5: Investor Presentation Q2FY19 – November 2, 2018
Investor Presentation Q2FY19 – November 2, 2018
Slide 6: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 7: Key Highlights of Q2FY19 and H1FY19
Key Highlights of Q2FY19 and H1FY19 • India Business: Adjusted for the change in the distribution policy and GST impact, the India business grew in double digit YoY in H1FY19 • Company’s secondary sales in H1FY19 grew by 16.4% - higher than IPM growth of 12.1% (Source: IQVIA MAT Sep. 2018) • Interna
Slide 8: Key Financial Highlights – Q2FY19 (Consolidated)
Key Financial Highlights – Q2FY19 (Consolidated) All figures in Rs mn Revenue from Operations India sales* 14,056 13,184 19,189 18,590 Q2FY18 Q2FY19 International sales 5,809 4,384 Q2FY18 Q2FY19 Q2FY18 Q2FY19 * YoY growth in India sales impacted by high base of Q2FY18 on account of inventory restock
Slide 9: Key Financial Highlights – Q2FY19 (Consolidated)
Key Financial Highlights – Q2FY19 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin YoY: 0.4% 4,545 11,509 11,550 3,642 61.9% 60.2% 24.4% 19.0% Q2FY18 Q2FY19 Q2FY18 Q2FY19 PBT (before Minority Interest) PAT (after Minority Interest) 3,207 4,321 2,545 3,260 Q2
Slide 10: Key Financial Highlights – H1FY19 (Consolidated)
Key Financial Highlights – H1FY19 (Consolidated) Particulars (Rs mn) H1FY19 H1FY18 YoY growth Revenue from Operations 35,780 31,680 12.9% Adjusting for the change in Gross Profit 21,479 18,975 13.2% distribution policy and GST impact, Gross Profit margin 60.0% 59.9% the underlying growth in India sa
Slide 11: India Business
India Business India Business: Q2FY19 Sales of Rs.13,184 million (6.2% YoY decline) • YoY growth in India sales was impacted by high base of Q2FY18 on account of inventory restocking post GST implementation • India sales contributed 69.4% to total sales in Q2FY19 • In Q2FY19 and H1FY19, Company’s se
Slide 12: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across most of the major therapeutic areas in Q2FY19 Established therapeutic Market rank 1 3 3 4 areas of Alkem 21.2% 18.9% 15.4% 14.9% 9.7% 11.5% 10.7% 5.6% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients
Slide 13: US Business
US Business US Business: Q2FY19 Sales of Rs.4,725 million (55.3% growth YoY) • US sales contributed 24.9% to total sales in Q2FY19 • Growth in the US business was driven by combination of new product launches and market share gains in the existing products. Depreciation of INR against USD also helpe
Slide 14: Steady progress in the US Business
Steady progress in the US Business US Sales (Rs mn) Cumulative ANDA filings and approvals 118 8,962 95 77 5,743 6,004 69 4,871 53 43 35 23 H1FY16 H1FY17 H1FY18 H1FY19 H1FY16 H1FY17 H1FY18 H1FY19 Total Approved (including tentative approvals) Total Filed
Slide 15: Update on US FDA inspection
Update on US FDA inspection Facility Scope Inspection Date Update Daman (India) Formulations March 2018 EIR received in July 2018 Successfully closed the inspection with zero Baddi (India) Formulations August 2018 observation Ankleshwar (India) API December 2016 EIR received in March 2017 Mandva (In
Slide 16: Other International Business
Other International Business Other International Business: Q2FY19 Sales of Rs.1,084 million (19.3% YoY decline) • Other International Market sales contributed 5.7% to total sales in Q2FY19 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS with key market
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on September 30, 2018 Non-Institution, 27.63% Promoter & Promoter Group, Institution, 65.92% 6.45% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other B
Slide 18: Thank You
ot. \ Thank You